Literature DB >> 2455756

Production and ELISA application of bispecific monoclonal antibodies against fluorescein isothiocyanate (FITC) and horseradish peroxidase (HRP).

L Karawajew1, O Behrsing, G Kaiser, B Micheel.   

Abstract

Hybrid hybridomas producing bispecific monoclonal antibodies reacting with both horseradish peroxidase (HRP) and fluorescein isothiocyanate (FITC) were obtained by fusing two hybridoma lines and selecting the fused cells using a fluorescence activated cell sorter (FACS). FITC was used to label different monoclonal antibodies and the bispecific antibodies acted as a linking agent between FITC-labelled antibody and the marker enzyme HRP. This system was used in enzyme immunoassays for the detection of different antigens. The results suggest a wide application of bispecific anti-FITC/anti-HRP antibodies as a detection system in EIA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455756     DOI: 10.1016/0022-1759(88)90064-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

1.  Use of bispecific antibodies in molecular velcro assays whose specificity approaches the theoretical limit of immunodetection for Bordetella pertussis.

Authors:  X L Tang; M S Peppler; R T Irvin; M R Suresh
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

Review 2.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

Review 3.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

4.  Suppression of well-established tumour xenografts by a hybrid-hybrid monoclonal antibody and vinblastine.

Authors:  W Smith; V A Gore; D R Brandon; D N Lynch; S A Cranstone; J R Corvalan
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Therapeutic effect of ansamitocin targeted to tumor by a bispecific monoclonal antibody.

Authors:  K Okamoto; K Harada; S Ikeyama; S Iwasa
Journal:  Jpn J Cancer Res       Date:  1992-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.